Q2 FY2026 Earnings
Financial report interval: 2026.03.30 - 2026.06.30
Overview: BioMarin Pharma(BMRN) the Revenue is 989.71 M (+19.91%), Beat estimate;the EBIT is 110.92 M (-59.94%), Beat estimate;the EPS is 0.23 (-81.3%), Miss estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueExceed expectations
0.99B19.91%
0.93B12.92%
+0.06B6.99%
EBITExceed expectations
0.11B59.94%
0.07B74.75%
+0.04B14.81%
EPSMiss expectations
0.2381.30%
0.370769.86%
-0.140711.44%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf